Key Takeaways:
Nektar Therapeutics (Nasdaq: NKTR) priced an upsized public offering of common stock to raise approximately $325 million in gross proceeds, a move that provides significant funding for its clinical trials but creates dilution for current investors.
The clinical-stage biotechnology company announced the pricing of 3,532,609 shares at $92.00 per share, according to a company press release. The offering is expected to close on April 23, 2026, subject to customary conditions.
Under the terms of the deal, Nektar is also granting underwriters a 30-day option to purchase up to an additional 529,891 shares. Jefferies, TD Cowen, and Piper Sandler are acting as joint bookrunning managers for the offering.
For investors, the offering presents a double-edged sword. While the infusion of capital is critical for the company's research and development, the issuance of new stock will dilute the ownership stake of existing shareholders, often putting short-term pressure on the stock price.
The company intends to use the net proceeds to advance its lead product candidate, rezpegaldesleukin (REZPEG). This novel, first-in-class regulatory T-cell stimulator is being evaluated in late-stage trials for treating autoimmune diseases.
A significant portion of the funds will support the planned Phase 3 trials for REZPEG in atopic dermatitis and alopecia areata. The capital will also support manufacturing and the advancement of other pipeline candidates, including preclinical antibody programs.
Stock offerings are a common financing tool for clinical-stage biotech companies, which often burn through significant cash reserves during lengthy and expensive drug development cycles. The $325 million raised will extend Nektar's cash runway, providing the necessary resources to reach key clinical milestones.
However, by increasing the number of shares outstanding, the offering reduces the earnings per share and ownership percentage for each existing shareholder. The long-term impact on shareholder value will ultimately depend on Nektar's ability to successfully develop and commercialize its drug candidates with the newly raised funds.
This article is for informational purposes only and does not constitute investment advice.
